Changes ahead for US list of drugs with safety concerns
This article was originally published in Scrip
The US FDAwill improve the transparency and context surrounding public disclosure of medicines that are being evaluated for safety issues. The agency "got the message" that improvements to its first quarterly listing of such products were needed, its center for drug evaluation and research's (CDER) director Dr Janet Woodcock told a drug safety conference cosponsored by the Drug Information Association, the FDA and PhRMA.
You may also be interested in...
Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.
US FDA cardiovascular and renal drugs panel will weigh approvability of the vasopressin analog during a nine-hour, online meeting 15 July; terlipressin was the focus of a 2009 complete response letter but met its primary endpoint in the recent CONFIRM trial.
Under certain circumstances, potential clinical trial participants may be able to provide informed consent by writing on a blank piece of paper that they voluntarily agree to participate in a given protocol, and texting or emailing a photo of the signed document to the investigator, the US FDA says in its latest guidance update.